(S)-4-Phenyl-2-(6-phenylpyridin-2-yl)-4,5-dihydrooxazole, 97%, 50mg

4-Bromo-2-methoxy-1-(trifluoromethyl)benzene, 95.0%, 5g

Microliter syringe GASTIGHT® series 1700 Point type 3, 25 µl, 1702 RNR, 1 piece

trans-4-(tert-Butoxycarbonylaminomethyl)cyclohexanecarboxylic Acid>98.0%(GC)(T)5g

4-(3-Bromopropyl)morpholin-3-one, 95%, 100mg

14-((2,5-DIOXOPYRROLIDIN-1-YL)OXY)-14-OXOTETRADECANOIC ACID, 95%, 1g

4-Methoxy-2-nitrophenol, 98.0%, 5g

H-Glu(OBzl)-OtBu.HCl, 95.0%, 5g

2,4-Dichloro-3-ethynyl-1,5-dimethoxybenzene, 95%, 1g

BOC-GLU(OTBU)-OME, 95.0%, 100mg

4-Methoxy-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester, 96%, 250mg

Dimethyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)phosphine oxide, 97%, 5g

tert-Butyl (4-cyanophenyl)carbamate, 95.0%, 1g